Treatment of recurrent ovarian cancer: A retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel - The Memorial Sloan-Kettering Cancer Center experience Academic Article Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Immunotherapy, Adoptive
  • Ovarian Neoplasms

abstract

  • Carboplatin as a single agent is effective therapy for recurrent ovarian cancer in women who recur following treatment with carboplatin and paclitaxel, and the treatment-free interval predicts response to single-agent carboplatin. However, our secondary analysis suggests that carboplatin and paclitaxel may produce a higher response rate and a survival benefit compared to C alone. This supports the conclusions of ICON4, which recently reported both overall and progression-free survival benefits with C + T over C in women with platinum-sensitive recurrent disease.

publication date

  • December 2003

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2003.08.017

PubMed ID

  • 14675681

Additional Document Info

start page

  • 584

end page

  • 90

volume

  • 91

number

  • 3